Percy H. Carter Sells 4,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Percy H. Carter sold 4,000 shares of Blueprint Medicines stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total value of $420,520.00. Following the sale, the insider now owns 41,895 shares in the company, valued at $4,404,421.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $103.34 on Friday. Blueprint Medicines Co. has a 52-week low of $43.89 and a 52-week high of $111.02. The company has a fifty day moving average of $98.57 and a 200-day moving average of $89.00. The company has a market capitalization of $6.47 billion, a P/E ratio of -21.48 and a beta of 0.70. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.32. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The firm had revenue of $96.12 million during the quarter, compared to analyst estimates of $82.58 million. As a group, equities research analysts predict that Blueprint Medicines Co. will post -5.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several research analyst reports. Barclays raised their price target on shares of Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Stifel Nicolaus raised their price target on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Citigroup boosted their price objective on Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research note on Friday, May 3rd. Stephens initiated coverage on Blueprint Medicines in a report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price objective on the stock. Finally, Leerink Partnrs raised Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $108.00.

Read Our Latest Report on BPMC

Institutional Trading of Blueprint Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Blueprint Medicines by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company’s stock worth $598,564,000 after acquiring an additional 195,007 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Blueprint Medicines by 15.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock worth $592,954,000 after purchasing an additional 821,868 shares during the period. Wellington Management Group LLP lifted its stake in Blueprint Medicines by 3.2% in the third quarter. Wellington Management Group LLP now owns 5,080,521 shares of the biotechnology company’s stock worth $255,144,000 after purchasing an additional 156,807 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Blueprint Medicines by 22.8% during the third quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company’s stock valued at $134,855,000 after buying an additional 498,622 shares during the period. Finally, Polar Capital Holdings Plc grew its stake in shares of Blueprint Medicines by 108.0% during the third quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company’s stock valued at $52,229,000 after buying an additional 540,000 shares during the last quarter.

About Blueprint Medicines

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Recommended Stories

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.